-
公开(公告)号：US12071425B2
公开(公告)日：2024-08-27
申请号：US17275606
申请日：2019-09-12
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Cuong Q. Ly , Georgette Castanedo , Paul Gibbons , Wendy Lee , Joachim Rudolph , Nicole Alice Blaquiere , Jacob Bradley Schwarz , Ramsay Beveridge , Jean-Philippe Leclerc , Alexandre Lemire , Leo Fu
IPC: C07D401/14 , A61K45/06 , C07D401/04 , C07D413/14 , C07D471/04 , C07D471/08
CPC classification number: C07D401/14 , A61K45/06 , C07D401/04 , C07D413/14 , C07D471/04 , C07D471/08
Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US20230057166A1
公开(公告)日：2023-02-23
申请号：US17275606
申请日：2019-09-12
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Cuong Q. Ly , Georgette Castanedo , Paul Gibbons , Wendy Lee , Joachim Rudolph , Nicole Alice Blaquiere , Jacob Bradley Schwarz , Ramsay Beveridge , Jean-Philippe Leclerc , Alexandre Lemire , Leo Fu
IPC: C07D401/14 , C07D401/04 , C07D413/14 , C07D471/04 , C07D471/08 , A61K45/06
Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US10435414B2
公开(公告)日：2019-10-08
申请号：US16044862
申请日：2018-07-25
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Keira Garland , Emily Hanan , Hans Purkey , Steven T. Staben , Robert Andrew Heald , Jamie Knight , Calum Macleod , Aijun Lu , Guosheng Wu , Siew Kuen Yeap
IPC: A61K31/4188 , A61K31/424 , A61K31/498 , A61K31/5365 , A61K45/06 , C07D498/04 , C07D498/06 , C07D519/00 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/5383 , A61K31/553 , C07D491/044
Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
-
公开(公告)号：US20230047209A1
公开(公告)日：2023-02-16
申请号：US17366923
申请日：2021-07-02
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Georgette Castanedo , Paul Gibbons , Joachim Rudolph , William Vernier , Ramsay Beveridge , Yao Wu , Guosheng Wu
IPC: C07D471/04 , C07D475/00
Abstract: Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods treating cancer, alone and in combination with other therapeutic agents.
-
公开(公告)号：US20220249487A1
公开(公告)日：2022-08-11
申请号：US17643623
申请日：2021-12-10
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Georgette Castanedo , Paul Gibbons , Joachim Rudolph , Yao Wu , Guosheng Wu
IPC: A61K31/517 , C07D401/12 , C07D239/84 , C07D401/04 , C07D401/14 , A61K31/573 , A61K38/07 , A61K31/69 , A61K31/454 , A61K39/395 , C07D405/14
Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.
-
Patent Agency Ranking
公开(公告)号：US20180327420A1
公开(公告)日：2018-11-15
申请号：US16044862
申请日：2018-07-25
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Keira Garland , Emily Hanan , Hans Purkey , Steven T. Staben , Robert Andrew Heald , Jamie Knight , Calum Macleod , Aijun Lu , Guosheng Wu , Siew Kuen Yeap
IPC: C07D498/04 , C07D519/00 , C07D498/06 , A61K31/5365 , A61K31/4188 , A61K31/498 , A61K31/4196 , C07D491/044 , A61K31/428 , A61K31/4439 , A61K31/5383 , A61K31/553 , A61K45/06 , A61K31/423
CPC classification number: C07D498/04 , A61K31/4188 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/498 , A61K31/5365 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D491/044 , C07D498/06 , C07D519/00
Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
-
公开(公告)号：US20170210733A1
公开(公告)日：2017-07-27
申请号：US15481764
申请日：2017-04-07
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Emily Hanan , Steven T. Staben , Robert Andrew Heald , Calum MacLeod , Richard Elliott
IPC: C07D413/14 , C07D267/08
CPC classification number: C07D413/14 , A61K31/553 , C07D267/08 , C07D498/04
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. Also described are methods of making the benzoxazepin oxazolidinone compounds having the Formula I structure.
-
公开(公告)号：US09643980B2
公开(公告)日：2017-05-09
申请号：US15200307
申请日：2016-07-01
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Emily Hanan , Steven T. Staben , Robert Andrew Heald , Calum MacLeod , Richard Elliott
IPC: A61K31/553 , C07D498/04 , C07D498/14 , C07D519/00 , A61K45/06
CPC classification number: C07D498/04 , A61K31/553 , A61K45/06
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
-
公开(公告)号：US10968203B2
公开(公告)日：2021-04-06
申请号：US15989008
申请日：2018-05-24
Inventor： Marie-Gabrielle Braun , Paul Gibbons , Wendy Lee , Cuong Ly , Joachim Rudolph , Jacob Schwarz , Avi Ashkenazi , Leo Fu , Tommy Lai , Fei Wang , Ramsay Beveridge , Liang Zhao
IPC: A61K31/506 , A61K45/06 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , A61P35/00
Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
10.发明申请公开(公告)号：US20180265497A1
公开(公告)日：2018-09-20
申请号：US15989008
申请日：2018-05-24
Inventor： Marie-Gabrielle Braun , Paul Gibbons , Wendy Lee , Cuong Ly , Joachim Rudolph , Jacob Schwarz , Avi Ashkenazi , Leo Fu , Tommy Lai , Fei Wang , Ramsay Beveridge , Liang Zhao
IPC: C07D401/14 , A61K31/506 , C07D401/04 , C07D405/14 , C07D417/14 , C07D413/14 , A61K45/06
CPC classification number: C07D401/14 , A61K31/506 , A61K45/06 , A61P35/00 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.03 seconds)
